REG - N4 Pharma PLC - Oral Delivery Update

N4 PharmaAnnouncement

18/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240418:nRSR0479La&default-theme=true

RNS Number : 0479L  N4 Pharma PLC  18 April 2024

 

18 April 2024

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Oral Delivery Update

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, is
pleased to provide a further positive update on its ongoing oral delivery
research work.

 

The Company, through its research program with the University of Queensland,
has undertaken further testing, in vivo, to show the successful delivery of a
Nuvec® capsule into the intestine where it has released its plasmid DNA
payload to produce localised protein expression. This work further
demonstrates the potential of Nuvec® as an oral delivery system for multiple
nucleotide payloads.

 

Specifically, in this experiment an enterically coated capsule containing
PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was
administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a
booster capsule at day 21. Protein expression was significantly higher than
control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which
subsequently dropped away by day 36. In addition, a significantly higher
ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec®
sample compared to control.

 

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"This work once more clearly shows that Nuvec® has the potential to be
developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many
potential applications such as a vaccination with plasmid DNA or to deliver a
local product for Irritable Bowel Disease or to treat colonic cancer among
many possible examples.

 

"We will continue to scope out the work needed to explore a potential
development program focusing on a specific oral application and further news
on this will be announced when a program is identified. In the meantime, the
University of Queensland will continue its work as part of our ARC funded
grant with them."

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                  Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub                    Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)

 To hear more, visit                                                  https://investors.n4pharma.com/link/oPBR0P
                                                                      (https://investors.n4pharma.com/link/oPBR0P)
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDSFLFUWELSELL